Recursion Pharmaceuticals Files 8-K
Ticker: RXRX · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
Related Tickers: RXRX
TL;DR
RXRX filed an 8-K on 10/29/25, standard procedure, no major news yet.
AI Summary
Recursion Pharmaceuticals, Inc. filed an 8-K on October 29, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event itself, such as financial transactions or material agreements, but confirms the company's ongoing reporting obligations.
Why It Matters
This 8-K filing indicates that Recursion Pharmaceuticals, Inc. has made a regulatory submission, which could be related to ongoing business operations or undisclosed material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' without disclosing specific material information, suggesting no immediate significant risk or opportunity.
Key Players & Entities
- RECURSION PHARMACEUTICALS, INC. (company) — Registrant
- October 29, 2025 (date) — Date of Report
- 001-40323 (other) — SEC File Number
- 46-4099738 (other) — I.R.S. Employer Identification No.
- 41 S Rio Grande Street (location) — Principal Executive Offices Address
- Salt Lake City, UT 84101 (location) — Principal Executive Offices City, State, Zip
FAQ
What specific event is Recursion Pharmaceuticals, Inc. reporting under 'Other Events' in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the 'Other Events' being reported; it only indicates that this section is being utilized.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on October 29, 2025.
What is Recursion Pharmaceuticals, Inc.'s SEC file number?
Recursion Pharmaceuticals, Inc.'s SEC file number is 001-40323.
Where are Recursion Pharmaceuticals, Inc.'s principal executive offices located?
Recursion Pharmaceuticals, Inc.'s principal executive offices are located at 41 S Rio Grande Street, Salt Lake City, UT 84101.
Is this filing related to a specific financial transaction or material agreement?
The filing is categorized under 'Other Events' and does not provide details of specific financial transactions or material agreements within the provided text.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2025-10-29 07:59:38
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
- $30 million — pay to the Company an Acceptance Fee of $30 million. SIGNATURES Pursuant to the requirem
Filing Documents
- rxrx-20251029.htm (8-K) — 18KB
- 0001601830-25-000152.txt ( ) — 129KB
- rxrx-20251029.xsd (EX-101.SCH) — 2KB
- rxrx-20251029_lab.xml (EX-101.LAB) — 21KB
- rxrx-20251029_pre.xml (EX-101.PRE) — 12KB
- rxrx-20251029_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 29, 2025, Recursion Pharmaceuticals, Inc. (the "Company" or "Recursion") announced the exercise of the option by Roche (as defined below) for a Microglia Map—a first-of-its-kind whole genome map of the brain's immune cells—generated by Recursion under the Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (collectively "Roche") dated December 5, 2021 (the "Agreement"). Pursuant to the terms of the Agreement, Roche will pay to the Company an Acceptance Fee of $30 million.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on October 29, 2025. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer